TransGenic Group

TransGenic Group Debt/Market Cap

The Debt to Market Capitalization Ratio of TransGenic Group (2342.T) as of Nov 18, 2026 is 41.01 %. In the previous year, Debt to Market Capitalization Ratio was 50.55 % — a change of -18.88% (lower).

Debt/Market Cap

41.01 %

YoY

-18.88%

Last updated:

Debt to Market Capitalization Ratio of TransGenic Group is 2026 41.01 % . Debt to Market Capitalization Ratio of TransGenic Group was 2025 50.55 % . It decreases by -18.88% lower compared to the previous year.

The TransGenic Group Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2019
13.26 JPY
Jan 1, 2020
35.87 JPY
Jan 1, 2021
40.35 JPY
Jan 1, 2022
36.60 JPY
Jan 1, 2023
47.66 JPY
Jan 1, 2024
44.28 JPY
Jan 1, 2025
50.55 JPY
Jan 1, 2026
41.01 JPY
The TransGenic Group Debt/Market Cap history
YEARDebt/Market CapYoY
41.01 %-18.88%
50.55 %+14.18%
44.28 %-7.09%
47.66 %+30.22%
36.60 %-9.31%
40.35 %+12.49%
35.87 %+170.45%
13.26 %-29.02%
18.69 %+287.30%
4.83 %-27.60%
6.66 %-23.82%
8.75 %-16.08%
10.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Debt to Market Capitalization Ratio of TransGenic Group is 41.01 % in 2026.

Debt to Market Capitalization Ratio of TransGenic Group changed from 50.55 % to 41.01 %, representing a -18.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's TransGenic Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — TransGenic Group

All Key Metrics — TransGenic Group